DCVac/PCa

BIOLOGICAL2 trials

Sponsors

SOTIO a.s.

Conditions

Castration-resistant Prostate CancerMetastatic Castration-resistant Prostate Cancer

Phase 1

A Phase I/II, Safety Clinical Trial of DCVAC/PCa and ONCOS-102 in Men With Metastatic Castration-resistant Prostate Cancer

TerminatedNCT03514836

SOTIO a.s.Castration-resistant Prostate Cancer

Start: 2018-05-23End: 2021-01-25Updated: 2021-02-01

Phase 3

Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer

CompletedNCT02111577

SOTIO a.s.Metastatic Castration-resistant Prostate Cancer

Start: 2014-05-26End: 2020-01-28Updated: 2021-04-06

Related Papers

Peripheral gene signatures reveal distinct cancer patient immunotypes with therapeutic implications for autologous DC-based vaccines

OncoImmunology2022-07-2215 citations

Efficacy and Safety of Autologous Dendritic Cell–Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer

JAMA Oncology2022-02-1081 citations

Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer

Journal for ImmunoTherapy of Cancer2019-11-14110 citations

Autologous dendritic cell vaccination (DCVAC/PCa) added to docetaxel chemotherapy in a double-blind, randomized phase III trial (VIABLE) in men with advanced (mCRPC) prostate cancer.

Journal of Clinical Oncology2015-05-207 citations